Vir’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

VIR is a biotechnology company that engages in developing and commercializing drugs for serious infectious diseases. Read more

VIR is a biotechnology company that engages in developing and commercializing drugs for serious infectious diseases. Read more

George Scangos's photo - President & CEO of Vir

President & CEO

George Scangos

CEO Approval Rating

92/100

Founded:

2016

Status:

PublicNASDAQVIR

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Morphotek is Vir's #1 competitor. Morphotek is a Private company that was founded in 2000 in Exton, Pennsylvania. Morphotek is in the Biotechnology industry. Compared to Vir, Morphotek has 176 fewer employees.

XOMA is seen as one of Vir's biggest rivals. XOMA was founded in Emeryville, California} in 1981. XOMA is in the Pharmaceuticals field. Compared to Vir, XOMA generates $10.2M less revenue.

Appili is one of Vir's top competitors. Appili is headquartered in Halifax, Nova Scotia, and was founded in 2015. Appili competes in the Biotechnology industry. Appili generates NaN% the revenue of Vir.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is ViroPharma a competitor of Vir?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$20.8M

Vir's revenue is the ranked 14th among it's top 10 competitors. The top 10 competitors average 2.7B. Over the last four quarters, Vir's revenue has grown by 2221.9%. Specifically, in Q2 2020's revenue was $67M; in Q3 2019, it was $1.4M; in Q2 2019, it was $2M; in Q3 2018, Vir's revenue was $2.9M.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Humabs BioMed SA

Sep 2017

Source »
undisclosed
Humabs BioMed develops human monoclonal antibodies for the treatment of infectious and inflammatory diseases.

These are all the companies that Vir has acquired. Vir's latest acquisition was Humabs BioMed SA in Sep 2017. Humabs BioMed develops human monoclonal antibodies for the treatment of infectious and inflammatory diseases.

Vir Funding History

$0$66M$209M

Since Vir was founded in 2016, it has participated in 3 rounds of funding. In total Vir has raised $209.0M. Vir's last funding round was on Oct 2019 for a total of $143.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Oct 2019
$143M

Equity
Jun 2018
$66M
-
Equity
Jan 2017
--

Total Funding: $209M

Since Vir was founded in 2016, it has participated in 3 rounds of funding. In total Vir has raised $209.0M. Vir's last funding round was on Oct 2019 for a total of $143.0M

Investments

No recent investments found related to Vir

Vir News

October 7, 2020Zacks

Stock Adds 6% in Session

Vir Biotechnology (VIR) saw a big move last session, as its shares jumped 6% on the day, amid huge vo... See more »
October 6, 2020The Business Journals: San Francisco Business Times

Vir, GSK move Covid antibody drug into late-stage clinical trial

In the six months since the San Francisco company and its partner announced their Covid-fighting coll... See more »
October 6, 2020Benzinga

Vir Biotech, GlaxoSmithKline Advance COVID-19 Antibody Treatment Into Global, Late-Stage Trial

Vir Biotechnology Inc (NASDAQ: VIR) shares were rallying Tuesday after the company provided an update... See more »
October 5, 2020MarketScreener

GSK to widen COVID-19 antibody treatment trial after safety clearance

(marketscreener.com) GlaxoSmithKline and partner Vir Biotechnology will expand their trial of an expe... See more »
September 10, 2020Benzinga

Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference

SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-st... See more »
September 4, 2020Zolmax News

Vir Biotechnology (NYSE:VIR) Expected to Post Quarterly Sales of $2.65 Million

Equities research analysts forecast that Vir Biotechnology (NYSE:VIR) will report sales of $2.65 mill... See more »

Vir Press Releases

April 15, 2020centralcharts

VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announc... See more »

Headquarters

499 Illinois Street Suite 500

San Francisco, California94158

415-906-4324

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

VIR is a biotechnology company that engages in developing and commercializing drugs for serious infectious diseases. Vir was founded in 2016. Vir's headquarters is located in San Francisco, California, USA 94158. It has raised 209.0M in 3 rounds. The ...

CEO

Vir's President & CEO, George Scangos, currently has an approval rating of 92%. Vir's primary competitors are Morphotek, XOMA & Appili.

Website

vir.bio

Frequently Asked Questions about Vir

  1. When was Vir founded?

    Vir was founded in 2016
  2. Who is Vir's CEO?

    Vir's CEO is George Scangos
  3. How much revenue does Vir generate?

    Vir generates $20.8M in revenue
  4. How much funding does Vir have?

    Vir has historically raised $209M in funding
  1. Where is Vir's headquarters?

    Vir's headquarters is in San Francisco California, USA
  2. How many employees does Vir have?

    Vir has 237 employees
  3. What sector does Vir operate in?

    Vir is in Biotechnology
  4. Who are Vir's competitors?

    Vir's top competitors are Morphotek, XOMA, Appili